Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Myovant Sciences's Enterprise Value is $933.7 Mil.
Myovant Sciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2022 was $-187.0 Mil. Therefore, Myovant Sciences's EV-to-EBIT ratio for today is -4.99.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Myovant Sciences's Enterprise Value is $933.7 Mil.
Myovant Sciences's EBITDA for the trailing twelve months (TTM) ended in Mar. 2022 was $-183.9 Mil. Therefore, Myovant Sciences's EV-to-EBITDA ratio for today is -5.08.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Myovant Sciences's Enterprise Value is $933.7 Mil.
Myovant Sciences's Revenue for the trailing twelve months (TTM) ended in Mar. 2022 was $231.0 Mil. Therefore, Myovant Sciences's EV-to-Revenue ratio for today is 4.04.
Myovant Sciences Enterprise Value Historical Data
The historical data trend for Myovant Sciences's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Myovant Sciences Annual Data
Trend
Mar16
Mar17
Mar18
Mar19
Mar20
Mar21
Mar22
Enterprise Value
1,232.43
1,663.32
724.82
1,557.57
1,197.22
Myovant Sciences Quarterly Data
Jun17
Sep17
Dec17
Mar18
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Enterprise Value
1,557.57
1,893.02
1,841.48
1,298.87
1,197.22
Competitive Comparison
For the Biotechnology subindustry, Myovant Sciences's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Myovant Sciences Enterprise Value Distribution
For the Biotechnology industry and Healthcare sector, Myovant Sciences's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Myovant Sciences's Enterprise Value falls into.
Myovant Sciences Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Myovant Sciences's Enterprise Value for the fiscal year that ended in Mar. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Myovant Sciences (NYSE:MYOV) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Myovant Sciences's current Enterprise Value is $933.7 Mil.
Myovant Sciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-187.0 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Myovant Sciences's current Enterprise Value is $933.7 Mil.
Myovant Sciences's EBITDA for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-183.9 Mil.
Myovant Sciences's current Enterprise Value is $933.7 Mil.
Myovant Sciences's Revenue for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $231.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Myovant Sciences Enterprise Value Related Terms
Thank you for viewing the detailed overview of Myovant Sciences's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Myovant Sciences Ltd is a healthcare company focused on redefining care for women and for men. The company's lead product candidate is relugolix, a once-daily, oral GnRH receptor antagonist. It has three late-stage clinical programs for relugolix in uterine fibroids, endometriosis, and prostate cancer. The company is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, that has completed a Phase 2a study for the treatment of female infertility as part of assisted reproduction.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
0.41(4.07%) Volume: 491,528 4:00PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NYSE:MYOV has been successfully added to your 
